What is the appropriate diagnostic workup, staging, and first‑line treatment for a newly diagnosed patient with non‑Hodgkin lymphoma, including both aggressive and indolent subtypes?

Non-Hodgkin Lymphoma: Diagnostic Workup, Staging, and First-Line Treatment

For newly diagnosed non-Hodgkin lymphoma, obtain an excisional lymph node biopsy for definitive diagnosis, perform comprehensive staging with PET-CT and bone marrow biopsy, and initiate treatment based on histologic subtype: R-CHOP (6-8 cycles) for aggressive CD20+ diffuse large B-cell lymphoma, or involved-site radiotherapy for localized indolent follicular lymphoma with observation or rituximab-based therapy for advanced-stage indolent disease. 1, 2

Diagnostic Approach

Tissue Acquisition

• Excisional lymph node biopsy is mandatory for initial diagnosis, providing adequate tissue for histopathology, immunohistochemistry, and molecular characterization 1, 2
• Core needle biopsies should only be performed when lymph nodes are inaccessible (e.g., retroperitoneal) or in rare emergency situations requiring immediate treatment 1
• Fine-needle aspiration is insufficient for reliable primary diagnosis and should be avoided 1

Critical pitfall: Core biopsies may miss histological grading heterogeneity in follicular lymphoma, potentially requiring rebiopsy 1

Pathology Requirements

• Diagnosis must follow WHO classification with immunohistochemistry results, particularly CD20 status 1
• Expert hematopathologist review is essential, especially for follicular lymphoma grades 3A/3B to distinguish aggressive from indolent disease 1
• Exclude Burkitt lymphoma and mantle cell lymphoma in aggressive presentations 1

Staging Workup

Essential Imaging

• PET-CT is the preferred staging modality for both aggressive and indolent lymphomas, replacing separate diagnostic CT scans 1, 2
• PET-CT is mandatory to confirm localized stage I/II disease before radiotherapy 1
• For follicular lymphoma and diffuse large B-cell lymphoma, PET-CT has near-universal positivity and superior accuracy for nodal and extranodal staging 1

Bone Marrow Evaluation

• Bone marrow aspirate and biopsy (minimum 20 mm length) is required for all lymphomas 1
• Exception: In low-bulk indolent stage III disease where observation is planned, bone marrow biopsy can be deferred as it won't alter management 1
• For early-stage indolent lymphoma (stage I/II), bone marrow biopsy is essential; bilateral cores are recommended if radioimmunotherapy is considered 1
• In early-stage diffuse large B-cell lymphoma, bone marrow involvement occurs in only 3.6% of cases, but biopsy remains standard practice 1

Laboratory Assessment

• Complete blood count, comprehensive metabolic panel 1
• Lactate dehydrogenase (LDH), β2-microglobulin, uric acid 1
• Immunoglobulin levels for B-cell lymphomas 1
• Mandatory infectious disease screening: HIV, hepatitis B, and hepatitis C 1, 2

Critical consideration: Hepatitis B screening is essential as reactivation can occur with rituximab-based therapy, potentially causing fatal hepatic failure 1

High-Risk Specific Evaluations

• Lumbar puncture with prophylactic intrathecal chemotherapy (cytarabine/methotrexate) for high-risk diffuse large B-cell lymphoma patients (IPI >2) with bone marrow, testicular, spinal, or skull base involvement 1

Prognostic Scoring

• Ann Arbor staging system with notation of bulky disease (>6 cm for follicular lymphoma, >10 cm for diffuse large B-cell lymphoma) 1, 2
• International Prognostic Index (IPI) must be calculated for aggressive lymphomas using age, LDH, performance status, stage, and extranodal sites 1, 2
• Follicular Lymphoma International Prognostic Index (FLIPI) for indolent disease 1

First-Line Treatment

Aggressive Lymphomas (Diffuse Large B-Cell Lymphoma)

Standard Therapy

• R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for 6-8 cycles every 21 days is the standard treatment for all stages of CD20+ disease 1, 2, 3
• Eight doses of rituximab should be administered 1
• Growth factor support (G-CSF) is indicated to maintain dose intensity and prevent febrile neutropenia 1, 2

Critical principle: Dose reductions for hematological toxicity must be avoided in curative-intent treatment; instead, use prophylactic G-CSF 1

Risk-Stratified Approach

• Young low-risk patients (IPI 0-1): Standard R-CHOP 1, 2
• Young high-risk patients (IPI ≥2): Standard R-CHOP, with high-dose chemotherapy and stem cell transplantation remaining experimental in first-line setting 1, 2
• Elderly patients (>60 years): Eight cycles of R-CHOP-21 regardless of risk category 2

Radiotherapy Considerations

• Consolidation radiotherapy to bulky disease sites has not proven benefit and is not routinely recommended 1
• For limited-stage disease, abbreviated chemotherapy followed by involved-field radiation may be considered 3, 4

Important caveat: Tumor lysis syndrome prophylaxis is essential in high tumor burden cases 1

Indolent Lymphomas (Follicular Lymphoma Grades 1,2, 3A)

Early-Stage Disease (Stage I/II)

• Involved-site radiotherapy (ISRT) is the standard treatment for localized follicular lymphoma 1
• PET-CT confirmation of true localized disease is mandatory before radiotherapy 1

Advanced-Stage Disease (Stage III/IV)

Treatment depends on disease burden and symptoms:

Asymptomatic, low tumor burden:

• Observation ("watch and wait") is appropriate 1
• Bone marrow biopsy can be deferred if observation is chosen 1

Symptomatic or high tumor burden requiring treatment:

• Rituximab-based chemotherapy regimens 1, 4
• Radioimmunotherapy is an option in selected cases 4

Key distinction: Follicular lymphoma grade 3B with sheets of centroblasts should be treated as aggressive lymphoma (like diffuse large B-cell lymphoma), not as indolent disease 1

Response Evaluation

Timing of Assessment

• Interim evaluation after 2-4 cycles to exclude progression 1, 2, 3
• End-of-treatment assessment after final cycle 1, 2
• Repeat assessment whenever adequate response is questioned 1

Imaging Modality

• PET-CT is preferred for response assessment in FDG-avid lymphomas (diffuse large B-cell lymphoma, follicular lymphoma) 1, 2, 3
• Baseline PET-CT is essential for interpreting post-treatment scans 1

Follow-Up Procedures

• Bone marrow biopsy or lumbar puncture should only be repeated at end of treatment if initially involved 1

Management of inadequate response: Patients with incomplete or lacking response must be immediately evaluated for salvage regimens 1, 2

Relapsed/Refractory Disease

Chemosensitive Relapse

• High-dose chemotherapy with autologous stem cell transplantation is the standard of care for chemosensitive relapsed aggressive lymphoma in suitable patients 2, 4
• Salvage regimens (R-DHAP, R-ICE, R-GEMOX) are used before transplantation 2

Patient Selection

• Age <65-70 years with adequate performance status 2
• Demonstrated chemosensitivity to salvage therapy 4, 5

Prognostic insight: Chemosensitive relapse predicts better outcomes with high-dose therapy compared to chemoresistant disease 5